Valuation: 3D Global Biotech Inc.

Market Cap 3.05B 94.19M 82.31M 75.96M 70.01M 132M 9.07B 135M 908M 357M 4.44B 354M 346M 15.29B P/E 2024
51.4x
P/E 2025 57.5x
Enterprise Value 2.62B 80.96M 70.76M 65.29M 60.18M 113M 7.8B 116M 780M 307M 3.82B 304M 297M 13.15B EV / Sales 2024
17x
EV / Sales 2025 16.1x
Free-Float
59%
Yield 2024
0.79%
Yield 2025 0.21%
1 day-1.86%
1 week+2.85%
Current month+16.28%
1 month+61.51%
3 months+24.29%
6 months-13.99%
Current year-17.91%
1 week 37.3
Extreme 37.3
41.95
1 month 23.8
Extreme 23.8
42.15
Current year 22.45
Extreme 22.45
49.4
1 year 22.45
Extreme 22.45
63
3 years 17.2
Extreme 17.2
73.5
5 years 17.2
Extreme 17.2
73.5
10 years 17.2
Extreme 17.2
76
Manager TitleAgeSince
Chief Executive Officer - 2015-01-14
Director of Finance/CFO - 2017-04-17
Director TitleAgeSince
Chairman - 2017-04-17
Director/Board Member - 2020-11-18
Director/Board Member - 2020-11-18
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+2.85%-21.49%+46.31% 94.19M
+0.20%+9.60%-18.86%-9.72% 175B
+0.11%-0.54%-7.34%-6.97% 106B
-0.92%-0.02%+4.58%+58.25% 59.91B
+0.66%+0.96%+37.64%+54.22% 51.95B
-0.96%+1.89%-10.61%-40.50% 43.58B
-1.62%-2.94% - - 33.65B
-0.31%-0.05%-9.19%-41.59% 29.58B
-0.03%-0.27%+70.76%-5.28% 25.31B
-0.95%-0.94%-3.43%-6.58% 21.23B
Average -0.58%+1.71%+4.67%+5.35% 54.72B
Weighted average by Cap. -0.23%+2.75%-1.71%+1.16%

Financials

2024 2025
Net sales 266M 8.2M 7.16M 6.61M 6.09M 11.49M 790M 11.74M 79.02M 31.08M 387M 30.79M 30.11M 1.33B 207M 6.38M 5.58M 5.14M 4.74M 8.94M 614M 9.14M 61.49M 24.19M 301M 23.96M 23.43M 1.04B
Net income 91.7M 2.83M 2.47M 2.28M 2.1M 3.96M 273M 4.05M 27.27M 10.73M 133M 10.63M 10.39M 459M 66.53M 2.05M 1.79M 1.66M 1.53M 2.88M 198M 2.94M 19.79M 7.78M 96.82M 7.71M 7.54M 333M
Net Debt -619M -19.1M -16.7M -15.41M -14.2M -26.77M -1.84B -27.36M -184M -72.43M -901M -71.75M -70.17M -3.1B -429M -13.23M -11.56M -10.67M -9.83M -18.53M -1.27B -18.94M -127M -50.14M -624M -49.67M -48.58M -2.15B
Logo 3D Global Biotech Inc.
3D Global Biotech Inc a biotechnology company mainly engaged in the development of medical materials for human reconstruction, focusing on the development of high-end medical equipment and biological printing technology. The Company mainly provides hard tissue reconstruction medical materials and soft tissue reconstruction medical materials. The hard tissue reconstruction medical materials mainly provide customized services for dental medical materials, original equipment manufacturer services for customized products of cranial implants, and orthopedics and dental reconstruction medical materials DGRA01: α-Former bone filling materials and the second-level medical equipment product of craniofacial jaw reconstruction medical materials DGRA03: SmileAlign transparent correction system. The soft tissue reconstruction medical materials mainly include bio-ink product DGRC02: 3D Bioture EX water gel stent.
Employees
-
Date Price Change Volume
26-07-17 NT$39.65 -1.86% 909,829
26-07-16 NT$40.40 -0.37% 639,089
26-07-15 NT$40.55 +6.15% 866,970
26-07-14 NT$38.20 -0.91% 795,906
  1. Stock Market
  2. Stocks
  3. 6808 Stock